Abbott Laboratories (ABT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2012 | 03-2012 | 12-2011 | 09-2011 | 06-2011 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 2,966,736 | 1,242,124 | 4,728,000 | 3,109,781 | 2,806,600 |
| Depreciation Amortization | 1,434,702 | 743,267 | 3,044,000 | 2,395,465 | 1,557,079 |
| Accounts receivable | 743,512 | 132,482 | -670,000 | 272,530 | 515,888 |
| Other Working Capital | 364,034 | -38,205 | 1,000 | 320,051 | 565,867 |
| Other Operating Activity | -1,217,225 | 145,262 | 1,867,000 | 1,470,901 | -931,136 |
| Operating Cash Flow | $4,291,759 | $2,224,930 | $8,970,000 | $7,568,728 | $4,514,298 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -878,446 | -453,330 | -1,491,000 | -1,216,765 | -764,770 |
| Net Acquisitions | -660,000 | -550,000 | -273,000 | -672,500 | -187,500 |
| Purchase Of Investment | N/A | N/A | -5,110,000 | N/A | N/A |
| Sale Of Investment | -2,677,257 | -3,899,584 | 5,649,000 | -1,093,548 | -3,025,737 |
| Other Investing Activity | 12,308 | 11,149 | 1,886,000 | 1,879,171 | 1,882,370 |
| Investing Cash Flow | $-4,203,395 | $-4,891,765 | $661,000 | $-1,103,642 | $-2,095,637 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 2,696,769 | 1,399,029 | -1,965,000 | -786,830 | 1,174,730 |
| Debt Issued | N/A | N/A | 1,000,000 | N/A | N/A |
| Debt Repayment | -54,000 | -54,000 | -3,012,000 | -2,008,836 | -2,006,679 |
| Common Stock Issued | 1,046,318 | 687,279 | 969,000 | 317,463 | 269,655 |
| Common Stock Repurchased | -1,722,114 | -987,686 | -77,000 | -74,428 | -73,845 |
| Dividend Paid | -1,565,532 | -758,548 | -2,938,000 | -2,186,006 | -1,434,376 |
| Other Financing Activity | -120,849 | -120,849 | -400,000 | 0 | 0 |
| Financing Cash Flow | $280,592 | $165,225 | $-6,423,000 | $-4,738,637 | $-2,070,515 |
| Exchange Rate Effect | -129,000 | 34,700 | -43,000 | -325,521 | 80,501 |
| Beginning Cash Position | 6,812,820 | 6,812,820 | 3,648,000 | 3,648,371 | 3,648,371 |
| End Cash Position | 7,052,776 | 4,345,910 | 6,813,000 | 5,049,299 | 4,077,018 |
| Net Cash Flow | $239,956 | $-2,466,910 | $3,165,000 | $1,400,928 | $428,647 |
| Free Cash Flow | |||||
| Operating Cash Flow | 4,291,759 | 2,224,930 | 8,970,000 | 7,568,728 | 4,514,298 |
| Capital Expenditure | -878,446 | -453,330 | -1,491,000 | -1,216,765 | -764,770 |
| Free Cash Flow | 3,413,313 | 1,771,600 | 7,479,000 | 6,351,963 | 3,749,528 |